ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) experienced a 3.1% rise in share value after the company’s CEO and Chairman, Dr. Stanley Crooke appeared on Jim Crammer’s how, Mad Money.
On the show, the CEO discussed Monday’s report about the new licensing agreement with Bayer AG (ADR) (OTCMKTS:BAYRY). The contract involves blood-thinning medication called FRXI or Factor 11. The drug is expected to be one of the top performers in the market
Crooke also revealed that despite the fact that the company has gotten into partnership agreements with numerous companies, Bayer is ideal because it is well familiar with the industry. He also stated that the company has the skill and commitment necessary for ensuring the success of Factor 11.
Isis plans to hold further talks to discuss the terms of the contract during the company’s earnings call on Tuesday. Isis is also scheduled to disclose information about the Diabetes and Muscular Dystrophy trials to the company’s shareholders. The drug manufacturer will also reveal more about Akcea Therapeutics, that is the company’s latest subsidiary. Akcea will place more focus on the development of lipid drugs.
Since Cramer acquired a portfolio in Isis stock in 2012, the company has experienced massive growth, with over 350% recorded increment. The Street Ratings Team, however, had a different perspective. The team gave Isis a Hold and gave the company a C score. In response to the ratings, the team cited their factors such as strengths, weaknesses, positive and negative performance as some of the factors influencing their ratings.
Isis strong suits can be summed up to the company’s strong share price performance, solid revenue growth and impressive progression in its net income. Unfortunately, there are factors pulling the company down such as unfavorable profit margins and a high debt management risk.
The company’s performance has generally been on a good path, but it could do better. Hopefully the new ventures and the positive influence will propel the company to more satisfactory performance in the future.